DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following:

  • Chronic myelogenous leukemia (CML), meeting 1 of the following criteria:

    • Under 21 years of age and in chronic phase

    • Ten to 75 years of age with CML in chronic phase, meeting 1 of the following criteria:

      • Failed or intolerant to prior treatment with imatinib mesylate
      • No prior therapeutic doses of imatinib mesylate within 12 months after disease diagnosis
    • Ten to 75 years of age with CML in accelerated phase or blast transformation

  • Acute lymphoblastic leukemia, meeting 1 of the following criteria:

    • In first remission with any of the following high-risk features:

      • WBC > 100,000/mm³ at diagnosis
      • Karyotypes t9; 22, t4, t19, t11, or biphenotypic leukemia
    • In second or subsequent remission
    • Primary induction failure
    • Partially responding or untreated relapsed disease

  • Acute myeloid leukemia (AML), meeting 1 of the following criteria:

    • In first remission

      • No AML with good-risk karyotypes (e.g., M3 [t15; 17], M4Eo [inv 16], t [8; 21])
    • In second or subsequent remission
    • Primary induction failure
    • Resistant relapsed disease

  • Myelodysplastic syndromes (MDS), including any of the following subtypes:

    • Refractory anemia with transfusion dependence
    • Refractory anemia with excess blasts
    • MDS in transformation to acute leukemia
    • Chronic myelomonocytic leukemia
    • Atypical MDS/myeloproliferative disorders

  • Myeloproliferative disorders, including any of the following subtypes:

    • Atypical (Philadelphia chromosome negative) chronic myelogenous or neutrophilic leukemias
    • Progressing myelofibrosis
    • Polycythemia vera
    • Essential thrombocythemia in transformation to acute leukemia
    • Essential thrombocythemia with progressive transfusion requirements or pancytopenia

  • Chronic lymphocytic leukemia

    • Refractory to fludarabine phosphate treatment AND meets 1 of the following criteria:

      • Bulky progressive disease
      • Thrombocytopenia (i.e., platelet count ≤ 100,000/mm^3) not due to recent chemotherapy
      • Anemia (i.e., hemoglobin ≤ 10 g/dL) not due to recent chemotherapy
  • Non-Hodgkin's lymphoma, including mantle cell lymphoma, that has relapsed or is refractory to standard-of-care treatments
  • Multiple myeloma or Waldenstrom's macroglobulinemia that is unresponsive to or relapsed after standard-of-care treatments
• HLA-identical (6/6) related donor available

PATIENT CHARACTERISTICS:

• Life expectancy ≥ 3 months
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No major anticipated illness or organ failure incompatible with survival from transplantation
• No severe psychiatric illness or mental deficiency that would preclude study compliance
• HIV negative
• DLCO ≥ 65% of predicted
• LVEF ≥ 40%
• AST ≤ 20 times upper limit of normal (ULN)
• Bilirubin ≤ 10 times ULN
• Creatinine ≤ 6 times ULN

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No prior allogeneic stem cell transplantation